@article{oai:tsukuba.repo.nii.ac.jp:00049384,
 author = {山田, 英恵 and YAMADA, Hideyasu and 佐藤, 浩昭 and SATOH, Hiroaki and Hida, Norihito and Yamagishi, Tetsuya and Hiroshima, Yoshinori and Yoshii, Shinichi and Saito, Takefumi and Hizawa, Nobuyuki},
 issue = {1},
 journal = {Anti-Cancer Drugs},
 month = {Jan},
 note = {Lung cancer is a major health concern worldwide, but new immunotherapeutic treatments for lung cancer have shown great promise and the prognosis for many severe cancers including lung cancer has been improving. In May 2017, the Food and Drug Administration approved pembrolizumab, a therapeutic antibody that blocks lymphocytic programmed death-1 (PD-1), as a first-line treatment for any solid tumor with specific genetic features. Pembrolizumab is a therapeutic antibody that blocks lymphocytic PD-1, the ligand of which (PD-L1) is expressed on tumor cells and which can prevent the immune system from recognizing and destroying tumors. Here, we report two cases of double cancer (case 1: lung and bladder cancer; case 2: gastric and lung cancer) in which pembrolizumab was effective for the treatment of both cancers in each patient.},
 pages = {105--109},
 title = {Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer},
 volume = {30},
 year = {2019},
 yomi = {ヤマダ, ヒデヤス and サトウ, ヒロアキ}
}